<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804375</url>
  </required_header>
  <id_info>
    <org_study_id>2PX-SP-02</org_study_id>
    <secondary_id>SMR-1850</secondary_id>
    <nct_id>NCT00804375</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain</brief_title>
  <official_title>Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smerud Medical Research International AS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SantoSolve AS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Smerud Medical Research International AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary: To compare the analgesic effect over 12 weeks of topical 2PX in stump pain.&#xD;
&#xD;
      Secondary: To prospectively measure other efficacy and safety variables of topical 2PX in&#xD;
      stump pain. Exploratory analyses will be performed to measure efficacy and safety variables&#xD;
      of topical 2PX in phantom pain&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average (stump) Pain Intensity (AsPI): and recorded in the diary in response to the question: 'What was your average stump pain intensity over the past 24 hours?' on a 100 mm VAS (0 = no pain, 100 = worst pain imaginable).</measure>
    <time_frame>will be measured each evening (at least 1 hour after taking off the prosthesis, if applicable, and immediately prior to administering the evening dose of study medication)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst (stump) Pain Intensity (WsPI): recorded in the diary in response to the question: 'What was your worst stump pain level during the past 24 hours?' on a 100 mm VAS (0 = no pain, 100 = worst pain imaginable).</measure>
    <time_frame>will be measured each evening (at least 1 hour after taking off the prosthesis, if applicable, and immediately prior to administering the evening dose of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Stump Pain</condition>
  <arm_group>
    <arm_group_label>2PX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pain medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2PX</intervention_name>
    <description>cutaneous solution to be applied twice daily for 84 days</description>
    <arm_group_label>2PX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>cutaneous solution to be applied twice daily for 84 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lower limb amputation at least 6 months prior to Visit 1. Amputation must be&#xD;
             transtibial, transfemoral or through the knee. For patients with transfemoral&#xD;
             amputation, the point of amputation must be ≥10 cm from the inguinal region.&#xD;
&#xD;
          -  Presenting with moderate-to-severe stump pain. For the purpose of this study, the&#xD;
             following criteria must all apply:&#xD;
&#xD;
               1. Stump pain commencing post amputation and continues at Visit 1 despite continued&#xD;
                  use of analgesic medication&#xD;
&#xD;
               2. Stump pain present on a daily basis&#xD;
&#xD;
               3. Stump pain intensity as Average stump Pain Intensity (AsPI) ≥40 on 100 mm VAS at&#xD;
                  Screening&#xD;
&#xD;
               4. Stump pain intensity at the randomisation visit: Mean (over the 7 day run-in&#xD;
                  period) AsPI rating ≥40 on a 100 mm VAS.&#xD;
&#xD;
               5. Pain at the site of the extremity amputation. The pain is located mainly in the&#xD;
                  stump itself. (Patients with concurrent phantom pain may be enrolled in the&#xD;
                  study.)&#xD;
&#xD;
               6. Stump pain persists despite proper healing of the stump&#xD;
&#xD;
          -  Outpatients, aged 18 years and above&#xD;
&#xD;
          -  Underlying therapy (e.g., rehabilitation procedures, analgesia, physio-therapy, spinal&#xD;
             cord stimulation (except for topical or subcutaneous local analgesics)) may be&#xD;
             continued throughout the duration of the study, if the regimen has been stable during&#xD;
             the 4 weeks immediately prior to Visit 1. If underlying therapy is continued during&#xD;
             the study the regimen must be maintained for the duration of the study.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with forefoot amputations alone are excluded from participation.&#xD;
&#xD;
          -  Patients who have received treatment with any topical or subcutaneously administered&#xD;
             analgesic agent for stump or phantom pain in the 4 weeks prior to study entry (i.e.&#xD;
             Visit 1).&#xD;
&#xD;
          -  Underlying therapy (e.g., rehabilitation procedures, analgesia, physio-therapy, spinal&#xD;
             cord stimulation) is not permitted if the regimen has not been stable in the 4 weeks&#xD;
             immediately prior to Visit 1.&#xD;
&#xD;
          -  After the 7 day run-in phase: patients taking any new or changing the dose of any&#xD;
             underlying analgesic medication (except for rescue medication as defined in this&#xD;
             protocol).&#xD;
&#xD;
          -  Patients with open wounds, burns or other non-intact skin at site(s) of study drug&#xD;
             administration (unhealed stumps).&#xD;
&#xD;
          -  Patients with significant discomfort from their prosthesis limiting use of the&#xD;
             prosthesis. Use of a prosthesis is not a requirement for participation in the study.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Female patients of childbearing potential unwilling to use adequate contraception&#xD;
             measures throughout the duration of the study. For the purpose of this study, adequate&#xD;
             contraception is defined as:&#xD;
&#xD;
               -  oral, injected or implanted hormonal methods of contraception; OR&#xD;
&#xD;
               -  placement of an intrauterine device (IUD) or intrauterine system (IUS); OR&#xD;
&#xD;
               -  barrier methods of contraception: Condom or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository Note: Male&#xD;
                  sterilization or abstinence are not acceptable methods of birth control and would&#xD;
                  preclude enrolment in the study.&#xD;
&#xD;
        Note: For post-menopausal women: less than 12 months since the last spontaneous menstrual&#xD;
        bleeding will exclude the patient unless they are willing to utilise acceptable methods of&#xD;
        contraception for the duration of the study.&#xD;
&#xD;
          -  Breast-feeding/lactating mothers&#xD;
&#xD;
          -  Any active malignant disease (except basal cell carcinoma; BCC)&#xD;
&#xD;
          -  Patients who have previously received 2PX.&#xD;
&#xD;
          -  Patients requiring concomitant administration of strontium ranelate (Protelos®)&#xD;
&#xD;
          -  Patients who have received an investigational drug or used an investigational device&#xD;
             within the 30 days prior to study entry.&#xD;
&#xD;
          -  Patients unable to comply with the study assessments&#xD;
&#xD;
          -  Patients with documented or suspected current alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lone Nikolajsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Macnair, PhD</last_name>
    <phone>+44 1357 523481</phone>
    <email>bob.macnair@smerud.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site in Herlev</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Århus</name>
      <address>
        <city>Århus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site in Hamar</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Stavern</name>
      <address>
        <city>Stavern</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Ålesund</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site in St.Petersburg</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site in Belfast</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Hammersmith</name>
      <address>
        <city>Hammersmith</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Crystal Palace</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Middlesborough</name>
      <address>
        <city>Middlesborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site in Newcastle</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>March 22, 2010</last_update_submitted>
  <last_update_submitted_qc>March 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Thorfinn Ege</name_title>
    <organization>SantoSolve AS</organization>
  </responsible_party>
  <keyword>stump pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

